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Isoniazid and rifampicin are considered the first-line medication for preventing and treating tuberculosis. 
Rifampicin is degraded in the stomach acidic environment, especially when combined with isoniazid, 
factor contributing to treatment failure. In this study, gastric-resistant isoniazid pellets were obtained 
to physical contact of this drug with rifampicin and to bypass the stomach´s acidic environment. The 
pellets were fabricated using the extrusion-spheronization technique. The coating process was conducted 
in a fluid spray coater using Acrycoat L 100® solution as the coating agent. The pellets obtained were 
submitted to a dissolution test in HCl 0.1 N and phosphate buffer media. The results indicated that 
optimum gastric-resistance was only attained with the highest amount of coating material, with isoniazid 
almost fully released in phosphate buffer. The amount of rifampicin released from its mixture with 
non-coated isoniazid pellets in HCl 0.1 N was less than that released from its mixture with the enteric-
coated pellets. Acrycoat L 100® was shown to be an effective enteric/gastric-resistant coating since the 
stability of rifampicin appeared to be enhanced when physical contact of this drug with isoniazid was 
prevented at low pH.
Uniterms: Rifampicin. Gastric-resistant isoniazids/pellets. Pellets/enteric coating. Acrycoat L 100®/
use/enteric coating.
Isoniazida e rifampicina são fármacos de primeira escolha para a prevenção e tratamento da tuberculose. 
A rifampicina degrada-se em condições ácidas do estômago, principalmente na presença da isoniazida, o 
que contribui para a falha do tratamento. O presente trabalho teve como objetivo a obtenção de péletes 
de isoniazida gastrorresistentes, visando a evitar contato da rifampicina com isoniazida e consequente 
degradação no meio ácido estomacal. Os péletes foram produzidos pela técnica de extrusão-esferonização. 
O processo de revestimento foi conduzido em leito fluidizado com solução orgânica de Acrycoat L 100®. 
Os péletes obtidos foram submetidos ao teste de dissolução em HCl 0,1 N e tampão fosfato. Os resultados 
indicam que a gastrorresistência foi obtida somente com a maior quantidade de revestimento, sendo a 
isoniazida liberada completamente no meio tampão fosfato. A quantidade de rifampicina dissolvida 
em meio ácido, quando associada a péletes de isoniazida não revestidos, foi menor do que a observada 
na presença de péletes de liberação entérica. O polímero Acrycoat L 100® mostrou-se eficiente para o 
recobrimento com a função de gastrorresistência, indicando que a instabilidade da rifampicina pode ser 
reduzida nas associações com a isoniazida através do revestimento entérico da isoniazida.
Unitermos: Rifampicina. Isoniazidas gastrorresistentes/péletes. Péletes/revestimento entérico. Acrycoat 
L 100®/uso/revestimento entérico.
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INTRODUCTION
Tuberculosis is one of the most common causes of 
infectious, disease-related mortality worldwide. Factors 
such as lack of patient compliance to the treatment regimen 
(which can take up to 9 months), development of multi-
resistant microorganisms and co-infection with the human 
immunodeficiency virus (HIV) have contributed to the 
failure of medical treatment and to increased mortality 
rates. In fact, multidrug-resistant tuberculosis remains 
the main cause of death among patients with HIV (WHO, 
2011).
The World Health Organization (WHO) and the 
International Union Against Tuberculosis and Lung 
Disease recommend the use of fixed doses of the first-
line drugs for tuberculosis treatment: rifampicin (RMP), 
isoniazid, (INH) pyrazinamide (PYR) and ethambutol 
(ETH) in order to assure adequate treatment (WHO, 
2011). However, rifampicin degrades in an acidic medium, 
especially when associated with isoniazid. RMP undergoes 
hydrolysis in an acid pH leading to 3-formylrifamycin 
(3-FRSV), which is poorly absorbed. In addition, 
this compound reacts with INH forming isonicotinyl 
hydrazone (HYD). HYD converts back to INH and 
3-FRSV resulting in significant recovery of INH with 
an eventual loss of RMP. The degradation rate of RMP 
was shown to be higher in the presence of INH in HCl 
0.1 N and simulated gastric fluid. Consequently, the dose 
available for absorption is significantly decreased (Shishoo 
et al., 1999; Singh et al., 2000, 2001).
The thermal behavior of binary mixtures of 
rifampicin and isoniazid polymorphic forms (I and II) 
has been determined by differential scanning calorimetry 
(DSC). The results showed that the different rifampicin 
polymorphic forms interacted with isoniazid. In addition, 
the mixture of both drugs became more thermally stable 
than each drug individually (Freire et al., 2009).
In order to overcome the reduction in bioavailability 
of rifampicin when associated with isoniazid, the 
development of a formulation that can minimize the 
interaction of these drugs in the GI tract appears to be a 
reasonable alternative. For this purpose, several delivery 
systems have been developed aiming to control the time 
and site of rifampicin/isoniazid delivery.
Alginate hydrogels have been used to produce 
microparticles for controlled release of rifampicin, 
isoniazid and pyrazinamide, whose release profiles have 
been determined in vitro and in vivo. It was shown that the 
bioavailability of these drugs was about 9 times higher 
than those of the non-encapsulated forms (Qurrat-Ul-Ain 
et al., 2003).
It has been reported that rifampicin is well absorbed 
from the stomach due to its maximum solubility in the pH 
range of 1-2, whereas isoniazid is less permeable through 
the stomach, but well absorbed from all three segments of 
the intestine (Shishoo et al., 1999). Therefore, the distinct 
physicochemical properties of these drugs, especially in 
terms of solubility and stability at different pH values, 
suggests that delivering each compound at different sites 
in the GI tract would be advantageous.
Gastric-resistant coatings, also called enteric 
coatings, have been used in oral solid dosage forms to 
overcome problems such as gastric mucosal irritation, 
poor oral bioavailability and incompatibility with 
other components in the formulation (Lecomte et al., 
2003). Gastric-resistant coatings are typically made 
from polymers whose solubility is pH dependent. 
Cellulose phthalates (acetate phthalate and hydroxypropyl 
methyl phthalate), polyvinyl phthalates, as well as 
polyacrylates and methacrylates (Eudragit and Acrycoat) 
are all insoluble in the acidic pH of the stomach 
and have been extensively used as enteric coatings 
(USP, 2007).
Gastric-resistant minitablets of isoniazid have been 
prepared using an organic solution of hydroxypropyl 
methylcellulose phthalate (HPMCP) as an enteric coating. 
The optimum formulation showed an acid resistance of 
two hours, while 90% of isoniazid was released within 15 
minutes in phosphate buffer pH 7.4. The performance of 
the enteric coating proved to be influenced by the amount 
of HPMCP in the nuclei as well as in the coating (Gohel, 
Sarvaiya, 2008).
A novel dosage form has been developed where 
two gastro retentive tablets of rifampicin and one enteric-
coated capsule of isoniazid, were placed in a hard gelatin 
capsule. The results showed that more than 90% of 
isoniazid was released within 30 minutes in an alkaline 
medium, whereas rifampicin was released over 4 hours. 
Moreover, since the physical contact between these drugs 
was reduced, the degradation of rifampicin was minimized 
(Gohel, Sarvaiya, 2007).
In another study, isoniazid pellets were coated with 
an aqueous suspension of Sureteric® resulting in only 10% 
isoniazid release in HCl 0.1 N over 120 minutes. However, 
the stability of rifampicin in these gastric-resistant pellets 
was not evaluated (Punda et al., 2010). In addition, Bhise 
et al., (2010) demonstrated that microspheres with high 
polymer content protected rifampicin from degradation in 
an acidic medium.
Thus, the aim of this study was to prepare gastric-
resistant isoniazid pellets to prevent direct physical contact 
between rifampicin and isoniazid and to investigate the 
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effectiveness of this formulation in reducing rifampicin 
degradation in an acidic medium.
MATERIAL AND METHODS
The following material was used: isoniazid 
(Zheijiang Jiangbei Pharm. Co, 20060707), rifampicin 
(Louhe Nanjiecun phar.G.P., 0710047), microcrystalline 
cellulose 101 (Blanver, 362/05) Acrycoat and Methocel 
E6. The other reagents were of analytical grade and used 
as received.
Preparation of isoniazid-containing pellets
Pellets were prepared by the extrusion-spheronization 
technique, where isoniazid and microcrystalline cellulose 
101 (85:15 weight ratio) were mixed in planetary mixer 
for 5 minutes. After the mixture was sieved through a 
1.0 mm mesh, an aqueous solution of Methocel E6 1% 
(w/v) was slowly added until a wet mass was obtained. The 
wet mass was then extruded using a radial extruder fitted 
with a screen having 1.0 mm diameter holes at 50 rpm. 
The extrudate was spheronized for 3min in a spheronizer 
at a rotation speed of 800 rpm. The pellets thus obtained 
were dried in a fluidized bed to about 1.5% moisture. 
Further, the pellets were sieved and particles of 1.0 mm 
in diameter were selected for the coating process. Bulk 
and tapped density, Carr index, Hausner factor, angle of 
repose and friability were determined according to the USP 
30 procedures and were used to characterize the pellets 
(USP, 2007).
Coating of pellets
The coating solution was obtained by dissolving 
the polymer Acrycoat L 100® in an isopropanol/ethanol 
mixture 1:1 (v:v) under magnetic stirring. Subsequently, 
triethyl citrate was added and the mixture stirred for an 
additional 10 minutes. The coating process was performed 
in a fluidized bed at inlet and atomizing pressures of 2.5 
and 2.0 bar, respectively; inlet and outlet air temperatures 
were 50 ºC and 37 ºC, respectively. The volume of the 
coating solution was previously adjusted to yield 15%, 
25% and 50% on weight increase with respect to the 
nuclei’s weight.
Dissolution of isoniazid pellets
Dissolution studies were carried out following the 
USP Dissolution Method for Extended Release. Accurately 
weighed pellets containing the equivalent of 200 mg 
of isoniazid (270.6, 294.1 and 353 mg for the pellets 
with 15, 25 and 50% in weight increase, respectively) 
were transferred to hard gelatin capsules (size 00). The 
dissolution apparatus I (ERWEKA DT6) was used to 
perform the dissolution tests at 37 °C and a rotation speed 
of 100 rpm. In order to simulate the GI tract conditions, the 
dissolution tests were first carried out in media at pH 1.2 
(HCl 0.1 N) and then at pH 6.8 (phosphate buffer), where 
the samples were allowed to remain in contact with each 
medium for 2 hours. Aliquots of 15 mL were withdrawn at 
60 and 120 minutes in pH 1.2 and at 15, 30 and 45 minutes 
in pH 6.8. After proper dilution, the amount of isoniazid 
was determined spectrophotometrically at 263 nm using a 
UV-vis spectrophotometer (VARIAN, CARY-50).
Dissolution of rifampicin in the presence of 
isoniazid pellets
In order to evaluate the influence of the presence 
of isoniazid on the dissolution of rifampicin in acidic 
medium, accurately weighed pellets (with and without 
coating) containing the equivalent of 200 mg of isoniazid 
were mixed with 300 mg of rifampicin and transferred 
to hard gelatin capsules (size 00). In addition, the 
effectiveness of the enteric coating in preventing the 
interaction of isoniazid with rifampicin was also evaluated. 
The release of both drugs was measured using the same 
apparatus and procedure described in the previous section 
with some minor modifications. Aliquots were withdrawn 
from the acidic medium (HCl 0.1 N) at 10, 15, 20, 30, 45 
and 60 minutes and the absorbance of the diluted solution 
measured by Ultra Fast Liquid Chromatography – tandem 
Diode Array Detection (UFLC/DAD) (Amorim, 2013).
A buffer solution composed of 50 g of ammonium 
acetate and 0.2 g of copper II acetate monohydrate diluted 
in 1.0 L water was freshly prepared, pH adjusted to 5.0 
using glacial acetic acid, mixed, filtered and degassed. The 
mobile phase was composed of two solutions: (A) buffer 
solution and methanol (94:6, v/v) from zero to 1.9 min 
and (B) buffer solution and acetonitrile (55:45, v/v), from 
2 to 4 min; both solutions were filtered and degassed. 
Standard and sample solutions were injected (2 µL) into 
the chromatograph after Millipore Millex-HV filtration 
(0.22 µm). The chromatographic UPLC XR analyses were 
performed by a Shimadzu device equipped with binary 
pump LC020AD XR, auto-sampler SIL-20AC XR, oven 
column CTO-20AC, and PDA detector SPD-M20A. In this 
study, a Shim-pack XR-ODS column (30 mm x 2 mm i.d., 
2.2 µm particle size) was used and the test performed 
at 30 °C, at a wavelength of 254 nm and flow rate of 
0.2 mL/min (Amorim, 2013).
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The dissolution profiles were compared based on 
the area under the curve (AUC) values obtained for RMP 
curves in the presence of coated and uncoated INH pellets, 
after integration from zero to 60 min.
RESULTS AND DISCUSSION
Rifampicin is well absorbed in the stomach due to its 
good solubility in the 1-2 pH range. On the other hand, the 
absorption of isoniazid at this pH is extremely poor, while 
most of its content is absorbed in the intestine (Shishoo, 
1999). Therefore, an alternative to reduce the degradation 
of rifampicin in the presence of isoniazid is the prevention 
of physical contact between these drugs, which can be 
achieved by enteric-coating of isoniazid. This approach 
would lead to the release of these drugs at different sites 
along the GI tract.
Although microparticulate systems represent a 
more costly and time consuming alternative, they have 
several advantages over regular dosage forms, such as 
a uniform and faster distribution over a larger GI area, 
as well as less variation in gastric residence time. These 
factors contribute to more uniform bioavailability among 
individuals and help reduce the risk of toxicity (Vervaet, 
Baert, Remon, 1995; Gandhi, Kaul, Panchagnula, 1999).
The pelletization technique produces spherical 
particles with different sizes and reasonable mechanical 
strength, where the experimental parameters can strongly 
influence the quality of the pellets and the success of the 
coating process (Feldon, McGinity, 2005).
In this study, the pellets obtained had a spherical and 
relatively regular shape (Figure 1), which resulted in good 
flow properties and narrow particle size distribution. These 
are desirable properties for coating.
Table I summarizes the results of non-coated pellet 
characterization, including bulk and tapped density, 
Hausner factor, Carr index, angle of repose, flow rate and 
friability.
In order to achieve successful pellet coating, the 
values of bulk and tapped densities should be as close 
as possible because a large difference between these 
values can lead to considerable variation in the amount 
of material that needed for coating (Lecomte et al., 2003; 
Vervaet, Baert, Remon, 1995; Gandhi, Kaul, Panchagnula, 
1999). In this study, comparison of the bulk and tapped 
densities indicates that the difference was relatively low. 
Moreover, the values of Hausner factor, Carr index and 
angle of repose indicate that the pellets have reasonable 
flow characteristics, which could be attributed to the 
pellets´ spherical shape. On the friability test, the pellets 
showed a weight loss of <1.5%, considered an optimum 
value for tablets. In fact, mechanically-resistant pellets are 
advantageous as they are expected to retain their physical 
integrity during the coating process (Lecomte et al., 2003; 
Vervaet, Baert, Remon, 1995; Gandhi, Kaul, Panchagnula, 
1999). Besides the amount of polymer solution (coating 
solution), the injection conditions are equally important in 
assuring a homogeneous coating layer on the nuclei, which 
can ultimately lead to more uniform drug release (Feldon, 
McGinity, 2005). The coated pellets had the same quality 
as the uncoated pellets.
In this study, the release profiles for non-coated 
and coated isoniazid pellets at pH 1.2 and 6.8 (simulating 
stomach and intestine, respectively) are shown in Figure 2.
As can be seen in Figure 2, the amount of isoniazid 
released from the non-coated pellets was higher than that 
released from the coated counterparts, where about 90% 
of the total drug content was released within the first 20 
minutes of the experiment, which appears to indicate that 
the nuclei did not interfere with drug release. On the other 
hand, as the amount of Acrycoat L 100 was increased on 
the pellets, the lag time for isoniazid release was increased. 
The pellets coated with lower amounts of polymer (15 and 
25% in weight increase) were not completely resistant 
at the stomach’s pH since 49.5 and 13.8% of the drug, 
TABLE I - Characterization of the non-coated pellets
Parameters Measured values
Bulk density 0.668 g/mL
Tapped density 0.690 g/mL
Hausner factor 1.03
Carr index 3.1%
Angle of repose 17.6°
Flow rate 30 g/s
Friability 0.5%
FIGURE 1 - Micrographs of isoniazid pellets.
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respectively, was released at 60 minutes of the experiment, 
whereas 85 and 37% was released within 2 hours. These 
values do not meet the USP standards for isoniazid release 
from gastric-resistant dosage forms.
When the volume of coating solution was increased 
(yielding a 50% weight increase) the amount of isoniazid 
released in HCl 0.1N was ~5.5% in 2 hours, which is in 
accordance with the USP 30 limits. On the other hand, 
after 45 minutes in phosphate buffer solution, 99.72% of 
this drug was released, which is above the minimum of 
80% established by the USP. This is due to the fact that 
pH-sensitive Acrycoat L 100 is ionized and solubilized 
at the intestine’s pH. Acrycoat L 100® is a copolymer of 
methacrylic acid Type A, which is soluble in intestinal 
fluids, whose pH is above 6. Due to the methyl groups 
in its structure, methacrylic acid is a weak acid (pKa 
4.66), which means that the coatings made of Acrycoat L 
100® are not ionized and hence poorly soluble at low pH 
(Lecomte et al., 2003; Feldon, McGinity, 2005).
In addition, our findings clearly show that the 
thickness of Acrycoat L 100 coating is an effective 
factor for resistance to dissolution at low pH. In fact, 
similar results were obtained when para-aminosalicylate 
pellets coated with Eudragit L-30 and D-55 (copolymer 
of methacrylic acid Type C) were prepared to eliminate 
the drug’s side effects and prevent its degradation at low 
pH. The polymer solution was able to coat the pellets 
yielding an increase in final weight of 40, 50 and 60%, 
where the latter sample was the most effective for reducing 
degradation of the drug (Siepmann et al., 2005).
Since our studies show that the pellets coated with 
the higher amount of Acrycoat L 100® were the most 
effective for preventing isoniazid release to the acidic 
medium, it was decided to use this concentration to prepare 
additional isoniazid-containing pellets and perform 
FIGURE 2 - Release of isoniazid from () non-coated pellets, 
and from those coated with Acrycoat L 100: () 15%, () 
25% and () 50% (from 0 to 120 min: pH=1.2; from 120 to 






















FIGURE 3 - Dissolution of rifampicin in the presence of () 























FIGURE 4 - UFLC/DAD chromatograms obtained during 
























dissolution tests with rifampicin in the presence of these 
pellets. The objective of this experiment was to compare 
the amount of rifampicin released from its mixture with 
non-coated isoniazid pellets against that released from its 
mixture with enteric-coated isoniazid samples. The UPLC 
method was used to detect possible degradation of RMP 
(Amorim, 2013).
Figure 3 shows the dissolution profiles of rifampicin 
from its mixture with non-coated and enteric-coated 
isoniazid pellets. As can be observed, RMP release from 
the capsules containing uncoated INH pellets reached 
80% at 15 min, and then RMP concentration decreased in 
the dissolution medium. In the presence of enteric-coated 
pellets, INH is not released to the medium (Figure 2) and 
RMP concentration remains higher comparing both profiles. 
AUC values calculated for the curves were 3951.77 and 
4406.99 respectively, indicating that when RMP/INH 
contact was avoided, the AUC increased by 11.5%.
Furthermore, the chromatograms obtained by 
UFLC/DAD at each time point of the dissolution profile of 
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rifampicin in the presence of non-coated isoniazid pellets 
show the reduction of RMP peak area and formation 
of a related product with time, a finding not observed 
in the presence of the coated pellets. This result is in 
agreement with the findings of Shishoo et al. (1999), 
who showed that 12% of rifampicin was degraded to 
3-formil-rifampicin (3-FRSV) in acidic medium after 45 
minutes on the dissolution test, whereas 21% of this drug 
was degraded in the presence of isoniazid under the same 
experimental conditions. Another study corroborated these 
findings by showing that the bioavailability of rifampicin 
was significantly reduced in the presence of isoniazid 
(Rahman, Ali, 2008).
Our results suggest that an interaction between 
isoniazid and rifampicin took place when both drugs 
were in contact with each other at low pH. Thus, enteric 
coating of isoniazid pellets appears to be an effective 
way of reducing its physical contact with rifampicin in 
the stomach. Acrycoat L 100® was shown to be effective 
as an enteric-coating material, representing a promising 
alternative to overcome the reduction in rifampicin’s 
bioavailability. Capsules containing rifampicin pellets 
for release in an acidic pH are being developed at our lab, 
where they will be fabricated using a one-way process.
CONCLUSIONS
In conclusion, the effectiveness of Acrycoat L 100® 
coatings in protecting isoniazid from acid degradation 
was strongly influenced by the amount used in the pellets 
obtained, where the extent of isoniazid dissolution 
established by the USP 30 was only achieved with higher 
amounts of Acrycoat L 100® solutions (sufficient to yield 
a 50% weight increase over non-coated pellets).
The extent of rifampicin dissolution in acidic 
medium in the presence of non-coated isoniazid pellets 
was lower than that with coated isoniazid pellets, 
which suggests that the use of enteric coating decreased 
the release of isoniazid in HCl 0.1 N and reduced the 
availability of this drug to react with rifampicin, which led 
to a decrease in rifampicin degradation at low pH.
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